|
gptkbp:instanceOf
|
gptkb:cancer
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:antigen
|
gptkb:CD19
gptkb:BCMA
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Novartis
gptkb:Bristol_Myers_Squibb
gptkb:Kite_Pharma
|
|
gptkbp:example
|
gptkb:Abecma
gptkb:Kymriah
gptkb:Yescarta
gptkb:Breyanzi
|
|
gptkbp:fullName
|
gptkb:Chimeric_Antigen_Receptor_T-cell_therapies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CAR-T therapies
|
|
gptkbp:limitation
|
high cost
complex manufacturing
limited efficacy in solid tumors
|
|
gptkbp:mechanismOfAction
|
genetically engineered T cells target cancer cells
|
|
gptkbp:processor
|
T cells collected from patient
Modified T cells infused back into patient
T cells expanded in laboratory
T cells genetically modified
|
|
gptkbp:relatedTo
|
gene therapy
monoclonal antibodies
T-cell therapy
|
|
gptkbp:researchArea
|
autoimmune diseases
solid tumors
|
|
gptkbp:sideEffect
|
neurotoxicity
cytokine release syndrome
|
|
gptkbp:usedFor
|
leukemia
B-cell lymphoma
hematologic malignancies
|
|
gptkbp:bfsParent
|
gptkb:Juno_Therapeutics_acquisition_by_Celgene
gptkb:Chimeric_Antigen_Receptor_T-cell_therapies
|
|
gptkbp:bfsLayer
|
7
|